NSRGF Stock Recent News

Nestle's share price is at a six-year low, offering a 4% dividend yield, presenting a potential entry point for value investors. Nestle's extensive brand portfolio, strong market presence, and robust cash generation make it a stable, defensive investment with limited downside risks. New CEO Laurent Freixe's experience and realistic growth targets, combined with potential efficiency improvements, could drive future growth and profitability.

Nestle has had a pretty woeful 2024, consistently missing consensus on organic sales growth while cutting guidance on several occasions. Management reset margin expectations at the company's recent Capital Markets Day. While fresh guidance looks underwhelming, the company should be free to push on from here. The ADSs are down roughly 30% year-to-date. Nestle only needs to deliver very modest free cash flow growth to justify the current price.

Nestle has stepped up its response to the launch of weight-loss drugs with a range of protein shots and drinks that it says can have the same impact. Boost Pre-meal is a liquid shot that will “support people using GLP-1 receptor agonists or other weight-loss medications”, said the Kit Kat maker.

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds, the latest effort by the world's biggest packaged food maker to tap the booming market for weight-loss products.

Former Nestle and Fresenius SE CEO Mark Schneider could succeed Jim Hagemann Snabe as chairman of the supervisory board of Siemens by 2027 at the latest, Siemens said on Wednesday, proposing Schneider's election.

Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections

GENEVA--(BUSINESS WIRE)--Lucien Selce and MKT Capital Ltd. (together, “we”), who collectively own 1.4 million shares of Seres Therapeutics Inc. (NASDAQ: MCRB) (“Seres” or the “Company”), today published the following open letter to the Company's Board of Directors (the “Board”). *** September 27, 2024 Members of the Board, We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Scienc.

Nestle has replaced its CEO Mark Schneider with company veteran Laurent Freixe in a bid to shake up its fortunes. The Swiss firm said in a statement Thursday that Schneider, who was at the helm for eight years, "has decided to relinquish his roles as CEO and member of the board of directors.

Nestle shares slumped Friday after the food giant abruptly announced the departure of its chief executive.

Britain's competition watchdog has decided not to pursue its probe into the infant formula and follow-on milk market, despite identifying a range of concerns. According to the Competition and Markets Authority, the combination of regulation, manufacturer behaviour, and customer needs has led to poor market outcomes.